On October 13, 2025, Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX) announced that its antibiotic Vibativ (telavancin) has been added to a national group purchasing agreement with Premier, Inc., effective October 1, 2025. The agreement allows Premier members to access Vibativ at pre‑negotiated pricing and terms for both the standard 12‑vial carton and a newly introduced 4‑vial Starter Pak.
Premier’s membership includes 4,350 U.S. hospitals and 325,000 other providers, giving Cumberland a broad distribution network across inpatient and outpatient settings. The 4‑vial Starter Pak offers a cost‑effective option for hospitals with lower patient volumes, while the 12‑vial carton remains the standard for high‑volume institutions.
This partnership expands Cumberland’s market reach, enhances product accessibility, and positions Vibativ for increased uptake in the U.S. acute‑care market, potentially driving higher sales volumes and strengthening the company’s competitive stance against other Gram‑positive antibiotics.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.